Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients.

Scientific reports - 3 Dec 2020

Chang Gee-Chen, Yang Tsung-Ying, Chen Kun-Chieh, Hsu Kuo-Hsuan, Huang Yen-Hsiang, Su Kang-Yi, Yu Sung-Liang, Tseng Jeng-Sen

Abstract excerpt

It remains unclear how programmed death-ligand 1 (PD-L1) expression interacts with anaplastic lymphoma kinase (ALK) mutation, its variants, and the outcome of treatment. One hundred and twenty four out of 1255 patients (9.9%) were deemed ALK-positive by the Ventana IHC assay. PD-L1 status and ALK variants were available in 100 and 59 patients, respectively. PD-L1 positive (TPS ≥ 1%) and strong positive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Cigarette Smoking

Share to Disease-Free Survival

Share to Lung Neoplasms

Share to Mutation

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 33273548
DOI: 10.1038/s41598-020-78152-1
PMCID: PMC7713243

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients.PMID 33273548Read ↗

Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

PD-L1 expression and its clinicopathologic and genomic correlation in the non-small cell lung carcinoma patients: An Indian perspective.Semantic proximity Read ↗

Clinical and molecular characteristics associated with high PD-L1 expression in EGFR-mutated lung adenocarcinoma.Semantic proximity Read ↗

Various impacts of driver mutations on the PD-L1 expression of NSCLC.Semantic proximity Read ↗

Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.Semantic proximity Read ↗

Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: A real-world study of 10 441 patients.Semantic proximity Read ↗

The impact of the ALK fusion variant on clinical outcomes in EML4-ALK patients with NSCLC: a systematic review and meta-analysis.Semantic proximity Read ↗

The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC.Semantic proximity Read ↗

Association between PD-L1 expression with EGFR, ALK, and ROS1 driver oncogene mutations in non-small cell lung cancerSemantic proximity Read ↗

A retrospective analysis of eleven gene mutations, PD-L1 expression and clinicopathological characteristics in non-small cell lung cancer patients.Semantic proximity Read ↗

Common driver mutations and programmed death-ligand 1 expression in advanced non-small cell lung cancer in smokers and never smokersSemantic proximity Read ↗

Strong programmed cell death ligand-1 affect clinical outcomes in advanced non-small cell lung cancer treated with third-generation epidermal growth factor receptor-tyrosine kinase inhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.